Zhitong Finance App News, Shiyao Group (01093.HK) announced that the Phase III clinical trial (HB1801-017) of injectable docetaxel (albumin binding) (HB1801) developed by the Group for the treatment of advanced breast cancer () has recently been officially launched at the first research center in China.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Shiyao Group (01093.HK) announced that the Phase III clinical trial (HB1801-017) of injectable docetaxel (albumin binding) (HB1801) developed by the Group for the treatment of advanced breast cancer () has recently been officially launched at the first research center in China.